Advertisement

Identification of a New Isoindole-2-yl Scaffold as a Qo and Qi Dual Inhibitor of Cytochrome bc 1 Complex: Virtual Screening, Synthesis, and Biochemical Assay

  • Homa Azizian
  • Kowsar Bagherzadeh
  • Sophia Shahbazi
  • Niusha Sharifi
  • Massoud Amanlou
Original Research Article
  • 149 Downloads

Abstract

Respiratory chain ubiquinol–cytochrome (cyt) c oxidoreductase (cyt bc 1 or complex III) has been demonstrated as a promising target for numerous antibiotics and fungicide applications. In this study, a virtual screening of NCI diversity database was carried out in order to find novel Qo/Qi cyt bc 1 complex inhibitors. Structure-based virtual screening and molecular docking methodology were employed to further screen compounds with inhibition activity against cyt bc 1 complex after extensive reliability validation protocol with cross-docking method and identification of the best score functions. Subsequently, the application of rational filtering procedure over the target database resulted in the elucidation of a novel class of cyt bc 1 complex potent inhibitors with comparable binding energies and biological activities to those of the standard inhibitor, antimycin.

Keywords

Cytochrome bc1 complex Virtual screening LibDock Scoring function Qo oxidative site Qi reductive site 

Notes

Acknowledgements

The authors are grateful to the Research Council of Tehran University of Medical Sciences for financial support to this research work.

References

  1. 1.
    Hunte C, Solmaz S, Palsdottir H, Wenz T (2008) A structural perspective on mechanism and function of the cytochrome bc (1) complex. Results Probl Cell Differ 45:253–278CrossRefGoogle Scholar
  2. 2.
    Mitchell P (1976) Possible molecular mechanisms of the protonmotive function of cytochrome systems. Theor Biol 62:327–367CrossRefGoogle Scholar
  3. 3.
    Crofts AR, Meinhardt SW (1982) A Q-cycle mechanism for the cyclic electron-transfer chain of Rhodopseudomonas sphaeroides. Biochem Soc Trans 10:201–203CrossRefGoogle Scholar
  4. 4.
    Iwata S, Lee JW, Okada K, Lee JK, Iwata M, Rasmussen B, Link TA, Ramaswamy S, Jap BK (1998) Complete structure of the 11-subunit bovine mitochondrial cytochrome bc 1 complex. Science 281:64–71CrossRefGoogle Scholar
  5. 5.
    Mitchell P (1975) Protonmotive redox mechanism of the cytochrome bc 1 complex in the respiratory chain: protonmotive ubquinone cycle. FEBS Lett 56:1–6CrossRefGoogle Scholar
  6. 6.
    Cape JL, Bowman MK, Kramer DM (2007) A semiquinone intermediate generated at the Qo site of the cytochrome bc 1 complex: importance for the Q-cycle and superoxide production. Proc Natl Acad Sci USA 104:7887–7892CrossRefGoogle Scholar
  7. 7.
    Pember SO, Fleck LC, Moberg WK, Walker MP (2005) Mechanistic differences in inhibition of ubiquinol cytochrome c reductase by the proximal Qo-site inhibitors famoxadone and methoxyacrylate stilbene. Arch Biochem Biophys 435:280–290CrossRefGoogle Scholar
  8. 8.
    Nixon GL, Pidathala C, Shone AE, Antoine T, Fisher N, O’Neill PM, Ward SA, Biagini GA (2013) Targeting the mitochondrial electron transport chain of Plasmodium falciparum: new strategies towards the development of improved antimalarials for the elimination era. Future Med Chem 13:1573–1591CrossRefGoogle Scholar
  9. 9.
    Nixon GL, Ward SA, O’Neill PM, Biagini GA (2014) Inhibitors of the Plasmodium mitochondrial respiratory chain. Encyclopedia of Malaria. pp:1–18Google Scholar
  10. 10.
    Lucumi E, Darling C, Jo H, Napper AD, Chandramohanadas R, Fisher N, Shone AE, Jing H, Ward SA, Biagini GA, DeGrado WF, Diamond SL, Greenbaum DC (2010) Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay. Antimicrob Agents Chemother 9:3597–3604CrossRefGoogle Scholar
  11. 11.
    Färnert A, Lindberg J, Gil P et al (2003) Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 326(7390):628–629CrossRefGoogle Scholar
  12. 12.
    Hughes W, Leoung G, Kramer F et al (1993) Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 328(21):1521–1527CrossRefGoogle Scholar
  13. 13.
    Djurković-Djaković O, Milenković V, Nikolić A, Bobić B, Grujić J (2002) Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of toxoplasma gondii. J Antimicrob Chemother 50(6):981–987CrossRefGoogle Scholar
  14. 14.
    Krause PJ, Lepore T, Sikand VK et al (2000) Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 343(20):1454–1458CrossRefGoogle Scholar
  15. 15.
    Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB (1999) Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Micro biol 33:704–711Google Scholar
  16. 16.
    McFadden DC, Tomavo S, Berry EA, Boothroyd JC (2000) Characterization of cytochrome b from toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. Mol Biochem Parasitol 108(1):1–12CrossRefGoogle Scholar
  17. 17.
    Zhao PL, Wang L, Zhu XL, Huang X, Zhan CG, Wu JW, Yang GF (2010) Subnanomolar inhibitor of cytochrome bc 1 complex designed by optimizing interaction with conformationally flexible residues. J Am Chem Soc 132:185–194CrossRefGoogle Scholar
  18. 18.
    Hao GF, Wang F, Li H, Zhu XL, Yang WC, Huang LS, Wu JW, Berry EA, Yang GF (2012) Computational discovery of picomolar Qo site inhibitors of cytochrome bc 1 complex. J Am Chem Soc 134:11168–11176CrossRefGoogle Scholar
  19. 19.
    Hao GF, Yang SG, Huang W, Wang L, Shen YQ, Tu WL, Li H, Huang LS, Wu JW, Berry EA, Yang GF (2015) Rational design of highly potent and slow-binding cytochrome bc 1 inhibitor as fungicide by computational substitution optimization. Sci Rep 5:13471–13481CrossRefGoogle Scholar
  20. 20.
    Cheng H, Shen YQ, Pan XY, Hou YP, Wu QY, Yang GF (2015) Discovery of 1,2,4 triazole-1,3-disulfonamides as dual inhibitors of mitochondrial complex ii and complex III. New J Chem 39:7281–7292CrossRefGoogle Scholar
  21. 21.
    Esser L, Yu CA, Xia D (2014) Structural basis of resistance to anti-cytochrome bc1 complex inhibitors: implication for drug improvement. Curr Pharm Des 20(5):704–724CrossRefGoogle Scholar
  22. 22.
    Rotsaert FAJ, Ding MG, Trumpower BL (2008) Differential efficacy of inhibition of mitochondrial and bacterial cytochrome bc 1 complexes by center N inhibitors antimycin, ilicicolin H and funiculosin. Biochim Biophys Acta 1777(2):211–219CrossRefGoogle Scholar
  23. 23.
    Berry EA, Huang LS, Lee DW, Daldal F, Nagai K, Minagawa N (2010) Ascochlorin is a novel, specific inhibitor of the mitochondrial cytochrome bc 1 complex. Biochim Biophys Acta 1797(3):360–370CrossRefGoogle Scholar
  24. 24.
    Gao X, Wen X, Esser L, Quinn B, Yu L, Yu CA, Xia D (2003) Structural basis for the quinone reduction in the bc1 complex: a comparative analysis of crystal structures of mitochondrial cytochrome bc1 with bound substrate and inhibitors at the Qi site. Biochemistry 42(30):9067–9080CrossRefGoogle Scholar
  25. 25.
    Huang L, Cobessi D, Tung EY, Berry EA (2005) Binding of the respiratory chain inhibitor antimycin to the mitochondrial bc 1 complex: a new crystal structure reveals an altered intramolecular hydrogen-bonding pattern description of the active site of bc 1 complex. J Mol Biol 351:573–597CrossRefGoogle Scholar
  26. 26.
    Discovery studio modeling environment, release 4.1 (2014). Accelrys Software Inc. San DiegoGoogle Scholar
  27. 27.
    Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev 6:3–26CrossRefGoogle Scholar
  28. 28.
    Esser L, Quinn B, Li Y, Zhang M, Elberry M, Yu L, Yu C, Xia D (2004) Crystallographic studies of quinol oxidation site inhibitors: a modified classification of inhibitors for the cytochrome bc 1 complex. J Mol Biol 341:281–302CrossRefGoogle Scholar
  29. 29.
    Diller DJ, Merz ML (2001) High throughput docking for library design and library prioritization. Proteins Struct Funct Gen 43:113–124CrossRefGoogle Scholar
  30. 30.
    Rao SN, Head MS, Kulkarni A, LaLonde JM (2007) Validation studies of the site-directed docking program LibDock. J Chem Inf Model 47:2159–2171CrossRefGoogle Scholar
  31. 31.
    Capper MJ, O’Neill PM, Fisher N, Strange RW, Moss D, Ward SA et al (2015) Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc 1. Proc Natl Acad Sci 112(3):755–760CrossRefGoogle Scholar
  32. 32.
    Azizian H, Mousavi Z, Faraji H, Tajik M, Bagherzadeh K, Bayate P, Shafiee A, Almasirad A (2016) Arylhydrazone derivatives of naproxen as new analgesic and anti-inflammatory agents: design, synthesis and molecular docking studies. J Mol Graph Model 67:127–136CrossRefGoogle Scholar
  33. 33.
    Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss PdbViewer: an environment for comparative protein modeling. Electrophoresis 18:2714–2723CrossRefGoogle Scholar
  34. 34.
    Krammer A, Kirchhoff PD, Jiang X, Venkatachalam CM, Waldman M (2005) LigScore: a novel scoring function for predicting binding affinities. J Mol Graph Model 23:395–407CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2017

Authors and Affiliations

  1. 1.Department of Medicinal Chemistry, School of Pharmacy, International CampusIran University of Medical SciencesTehranIran
  2. 2.Razi Drug Research CenterIran University of Medical SciencesTehranIran
  3. 3.Department of Medicinal Chemistry, Faculty of Pharmacy and Drug Design and Development Research CenterTehran University of Medical SciencesTehranIran

Personalised recommendations